​

Gilead Sciences (GILD) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Gilead Sciences Revenue Highlights

Latest Revenue (Y)

$27.12B

Latest Revenue (Q)

$7.55B

Main Segment (Y)

Product

Main Geography (Y)

UNITED STATES

Gilead Sciences Revenue by Period

Gilead Sciences Revenue by Year

DateRevenueChange
2023-12-31$27.12B-0.60%
2022-12-31$27.28B-0.09%
2021-12-31$27.30B10.60%
2020-12-31$24.69B9.98%
2019-12-31$22.45B1.46%
2018-12-31$22.13B-15.24%
2017-12-31$26.11B-14.09%
2016-12-31$30.39B-6.89%
2015-12-31$32.64B31.13%
2014-12-31$24.89B122.20%
2013-12-31$11.20B15.45%
2012-12-31$9.70B15.71%
2011-12-31$8.39B5.48%
2010-12-31$7.95B13.38%
2009-12-31$7.01B31.40%
2008-12-31$5.34B26.14%
2007-12-31$4.23B39.78%
2006-12-31$3.03B49.19%
2005-12-31$2.03B53.13%
2004-12-31$1.32B52.63%
2003-12-31$867.86M85.92%
2002-12-31$466.79M99.68%
2001-12-31$233.77M19.54%
2000-12-31$195.56M15.71%
1999-12-31$169.00M418.40%
1998-12-31$32.60M-18.50%
1997-12-31$40.00M19.76%
1996-12-31$33.40M1137.04%
1995-12-31$2.70M-34.15%
1994-03-31$4.10M-2.38%
1993-03-31$4.20M-

Gilead Sciences generated $27.12B in revenue during NA 2023, up -0.60% compared to the previous quarter, and up 122.55% compared to the same period a year ago.

Gilead Sciences Revenue by Quarter

DateRevenueChange
2024-09-30$7.55B8.65%
2024-06-30$6.95B3.93%
2024-03-31$6.69B-6.03%
2023-12-31$7.12B0.92%
2023-09-30$7.05B6.83%
2023-06-30$6.60B3.89%
2023-03-31$6.35B-14.03%
2022-12-31$7.39B4.93%
2022-09-30$7.04B12.49%
2022-06-30$6.26B-5.01%
2022-03-31$6.59B-9.03%
2021-12-31$7.24B-2.39%
2021-09-30$7.42B19.37%
2021-06-30$6.22B-3.21%
2021-03-31$6.42B-13.45%
2020-12-31$7.42B12.83%
2020-09-30$6.58B27.88%
2020-06-30$5.14B-7.30%
2020-03-31$5.55B-5.63%
2019-12-31$5.88B4.91%
2019-09-30$5.60B-1.42%
2019-06-30$5.68B7.65%
2019-03-31$5.28B-8.87%
2018-12-31$5.79B3.56%
2018-09-30$5.60B-0.92%
2018-06-30$5.65B11.01%
2018-03-31$5.09B-14.47%
2017-12-31$5.95B-8.65%
2017-09-30$6.51B-8.81%
2017-06-30$7.14B9.78%
2017-03-31$6.50B-11.13%
2016-12-31$7.32B-2.40%
2016-09-30$7.50B-3.55%
2016-06-30$7.78B-0.23%
2016-03-31$7.79B-8.37%
2015-12-31$8.51B2.54%
2015-09-30$8.29B0.62%
2015-06-30$8.24B8.56%
2015-03-31$7.59B3.82%
2014-12-31$7.31B21.06%
2014-09-30$6.04B-7.55%
2014-06-30$6.53B30.73%
2014-03-31$5.00B60.23%
2013-12-31$3.12B12.11%
2013-09-30$2.78B0.56%
2013-06-30$2.77B9.31%
2013-03-31$2.53B-2.19%
2012-12-31$2.59B6.66%
2012-09-30$2.43B0.89%
2012-06-30$2.41B5.38%
2012-03-31$2.28B3.73%
2011-12-31$2.20B3.71%
2011-09-30$2.12B-0.73%
2011-06-30$2.14B10.96%
2011-03-31$1.93B-3.63%
2010-12-31$2.00B3.15%
2010-09-30$1.94B0.54%
2010-06-30$1.93B-7.60%
2010-03-31$2.09B2.63%
2009-12-31$2.03B12.82%
2009-09-30$1.80B9.36%
2009-06-30$1.65B7.62%
2009-03-31$1.53B7.16%
2008-12-31$1.43B4.15%
2008-09-30$1.37B7.29%
2008-06-30$1.28B1.59%
2008-03-31$1.26B-

Gilead Sciences generated $7.55B in revenue during Q3 2024, up 8.65% compared to the previous quarter, and up 114.41% compared to the same period a year ago.

Gilead Sciences Revenue Breakdown

Gilead Sciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 20Dec 19Dec 18
Royalty, Contract, And Other$182.00M$334.00M$330.00M$450.00M
Oncology Product$2.93B---
Products, Other HIV$18.23B---
Hepatitis B Virus / Hepatitis Delta Virus Product$1.02B---
Trodelvy$1.06B---
Veklury$2.18B---
Other Products, Total Other product sales$859.00M---
Cell Therapy Products, Total Cell Therapy Product Sales$2.24B---
Product$26.93B---

Gilead Sciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (48.41%), Products, Other HIV (32.77%), Oncology Product (5.27%), Cell Therapy Products, Total Cell Therapy Product Sales (4.02%), Veklury (3.93%), Trodelvy (1.91%), Hepatitis B Virus / Hepatitis Delta Virus Product (1.83%), Other Products, Total Other product sales (1.54%), and Royalty, Contract, And Other (0.33%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Products, Other HIV$5.07B$4.34B$4.71B--------
Other Products, Total Other product sales$201.00M$224.00M$201.00M--------
Trodelvy$332.00M$309.00M$298.00M--------
Veklury$692.00M$555.00M$719.00M--------
Cell Therapy Products, Total Cell Therapy Product Sales$970.00M$960.00M---------
Oncology Product--$2.16B$769.00M-------
Product--$19.94B$6.99B$6.49B$5.07B$5.47B----
Royalty, Contract, And Other--$126.00M$56.00M$83.00M$88.00M$78.00M$81.00M---
Hepatitis B Virus / Hepatitis Delta Virus Product--$259.00M--------

Gilead Sciences's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Products, Other HIV (69.80%), Cell Therapy Products, Total Cell Therapy Product Sales (13.35%), Veklury (9.52%), Trodelvy (4.57%), and Other Products, Total Other product sales (2.77%).

Gilead Sciences Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Europe$4.31B$702.00M$1.09B$241.00M$244.00M
UNITED STATES$19.44B$1.57B$3.64B$76.00M$80.00M
Other International$3.37B----

Gilead Sciences's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (71.68%), Europe (15.89%), and Other International (12.42%).

Quarterly Revenue by Country

CountrySep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
UNITED STATES$5.45B$4.63B$5.18B$5.02B$189.00M$252.00M$396.00M$336.00M$41.00M$801.00M$877.00M$1.53B$416.00M$820.00M$21.00M$24.00M$14.00M$17.00M$19.00M$20.00M
Europe$1.17B$1.16B$1.16B$1.04B$52.00M$111.00M$142.00M$130.00M$126.00M$304.00M$334.00M$109.00M$264.00M$388.00M$71.00M$937.00M$62.00M$48.00M$63.00M$67.00M
Other International-$894.00M$765.00M-----------------

Gilead Sciences's latest quarterly revenue breakdown by geography, as of Sep 24: UNITED STATES (82.36%), and Europe (17.64%).

Gilead Sciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
JNJJohnson & Johnson$85.15B$22.47B
MRKMerck$60.12B$16.66B
PFEPfizer$58.50B$17.70B
ABBVAbbVie$54.32B$14.46B
AZNAstraZeneca$45.81B$12.68B
BMYBristol-Myers Squibb$45.01B$11.89B
LLYEli Lilly and$34.12B$11.44B
AMGNAmgen$28.19B$8.50B
GILDGilead Sciences$27.12B$7.55B

GILD Revenue FAQ

What is Gilead Sciences’s yearly revenue?

Gilead Sciences's yearly revenue for 2023 was $27.12B, representing a decrease of -0.60% compared to 2022. The company's yearly revenue for 2022 was $27.28B, representing a decrease of -0.09% compared to 2021. GILD's yearly revenue for 2021 was $27.3B, representing an increase of 10.60% compared to 2020.

What is Gilead Sciences’s quarterly revenue?

Gilead Sciences's quarterly revenue for Q3 2024 was $7.55B, a 8.65% increase from the previous quarter (Q2 2024), and a 7.09% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $6.95B, a 3.93% increase from the previous quarter (Q1 2024), and a 5.30% increase year-over-year (Q2 2023). GILD's quarterly revenue for Q1 2024 was $6.69B, a -6.03% decrease from the previous quarter (Q4 2023), and a 5.26% increase year-over-year (Q1 2023).

What is Gilead Sciences’s revenue growth rate?

Gilead Sciences's revenue growth rate for the last 3 years (2021-2023) was -0.69%, and for the last 5 years (2019-2023) was 20.79%.

What are Gilead Sciences’s revenue streams?

Gilead Sciences's revenue streams in c 23 are Royalty, Contract, And Other, Oncology Product, Products, Other HIV, Hepatitis B Virus / Hepatitis Delta Virus Product, Trodelvy, Veklury, Other Products, Total Other product sales, Cell Therapy Products, Total Cell Therapy Product Sales, and Product. Royalty, Contract, And Other generated $182M in revenue, accounting 0.33% of the company's total revenue, down -45.51% year-over-year. Oncology Product generated $2.93B in revenue, accounting 5.27% of the company's total revenue Products, Other HIV generated $18.23B in revenue, accounting 32.77% of the company's total revenue Hepatitis B Virus / Hepatitis Delta Virus Product generated $1.02B in revenue, accounting 1.83% of the company's total revenue Trodelvy generated $1.06B in revenue, accounting 1.91% of the company's total revenue Veklury generated $2.18B in revenue, accounting 3.93% of the company's total revenue Other Products, Total Other product sales generated $859M in revenue, accounting 1.54% of the company's total revenue Cell Therapy Products, Total Cell Therapy Product Sales generated $2.24B in revenue, accounting 4.02% of the company's total revenue Product generated $26.93B in revenue, accounting 48.41% of the company's total revenue

What is Gilead Sciences’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Gilead Sciences was Product. This segment made a revenue of $26.93B, representing 48.41% of the company's total revenue.